Heartflow Inc. upped the price of shares in its IPO for a second time to $19 on Aug. 7 before opening on the Nasdaq as “HTFL” ...

Minghui Pharmaceutical Ltd. announced it is raising $131 million in a pre-IPO financing round Aug. 7. The funds will be used to advance its cancer and inflammatory disease pipeline, which include a PD ...

Although congenital aortic valve disease (AVD) is one of the most prevalent types of congenital heart disease, affecting 1% ...

Ischemic stroke triggers a strong neuroinflammatory response, with microglial activation and neutrophil infiltration ...

Proteinqure Inc. has received regulatory clearances from the U.FDA and Health Canada to initiate a phase I trial of lead ...

The Nipah virus (NiV) from the Henipavirus genus is a bat-borne zoonotic pathogen that causes encephalitis and acute ...

Med-tech companies brought in $18.11 billion through financings in the first seven months of 2025, marking a modest rebound ...

Biopharma companies raised $34.89 billion through financings in the first seven months of 2025, including $5.66 billion in ...

In the tumor microenvironment, cancer cells activate various signaling pathways to promote their growth. This includes the ...

K36 Therapeutics Inc. has obtained IND clearance from the U.S. FDA for KTX-2001, a selective, oral, small-molecule inhibitor of nuclear receptor-binding SET domain protein 2 (NSD2), a histone ...

Dana-Farber Cancer Institute Inc. has divulged ubiquitin carboxyl-terminal hydrolase 28 (USP28; KIAA1515) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.

Methicillin-resistant Staphylococcus aureus (MRSA) is the leading cause of nosocomial infections, with an increasing prevalence worldwide. Researchers aimed to apply a new approach called ...